Fig. 2From: INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignanciesDecision boundaries for futility and efficacy in terms of number of observed responders among enrolled patients. The same criteria apply for interim and final analysesBack to article page